Clinical Trial Update: Study of Diagnostic Performance of [18F]CTT1057 in BCR [Phase 3]

View source ↗

Summary

Novartis completed a Phase 3 trial evaluating the diagnostic performance of the radiopharmaceutical [18F]CTT1057 in detecting biochemical recurrence of prostate…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• [18F]CTT1057 (CTT1057)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Prostatic Neoplasms, Prostate Cancer | Phase 3 | Status: COMPLETED | Results posted: 2025-03-12